在HR+患者中,HER2 零表达和 HER2 低表 达(对数秩检验 P=0.4285)之间的 RFS 曲线没有统计学差异(图3)。多变量分析发现,仅较高 的初始cAJCC分期(P=0.003)与较差的RFS独立相关(表 3)。对于HR+eBC患者的OS,单变量分析表明,只有cN...
[1] Erika P. Hamilton, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.2024 ASCO 1025...
[1] Erika P. Hamilton, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.2024 ASCO 1025P. [2] Cristina Saura, et al. Pooled analysis by best confirmed response...
近日，来自美国耶鲁大学的Lajos Pusztai团队在Cancer Cell上在线发表题为Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial 的文章，报道了一项用于II/III期早期乳腺癌的I-SPY2试验结果，显示度伐利尤与奥拉帕尼联...
2. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med.2020; 54(1): 34-44. 3. Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.Mol Biol In...
2023年3月30日,空军军医大学第二附属医院普通外科包国强教授团队在乳腺癌期刊《Breast Cancer Research》发表了题为“Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low”的研究成果。该研究通过对三阴性乳腺癌(TNBC)患者进行为期8年的随访调查、并且...
[1]https://www.onclive.com/view/antibody-drug-conjugates-expand-her2-breast-cancer-treatment-options [2]DS-8201a in pre-treated HER2 breast cancer that cannot be surgically removed or has spread [DESTINY-Breast02]. ClinicalTrials.gov. Updated August 12, 2022. Accessed November 28, 2022. ...
3、Jackisch, Christian et al. “HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.” European journal of cancer (...
4.Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer : Subgroup analyses from the Randomized Phase 3 DESTINY-Breast03 Study. 2021SABCS.GS3-01. 5.Sadowska AM, et al. Expert Rev Anticancer Ther. 2013;13(8):997-1006. ...
2.Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020; 54(1): 34-44. 3.Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol ...